In the past 48 hours, the healthcare industry shows robust M&A activity amid pricing pressures and service disruptions. Merit Medical Systems acquired View Point Medical for about 140 million USD, including 90 million in cash, to bolster its medical device portfolio.[2] Neurocrine Biosciences announced a 2.9 billion USD buyout of Soleno Therapeutics, gaining FDA-approved Vykat XR for rare diseases.[6] Office Ally bought Jopari Solutions to enhance claims processing,[8] while Hologic finalized its 18.3 billion USD sale to private equity firms.[10] LongueVue Capital invested in Apex Dental Laboratory Group, operating 16 labs across 12 states.[4]

Pricing shifts dominate: AbbVie and Genentech joined the TrumpRx site, offering Humira at an 86% discount to 950 USD from over 6,900 USD for uninsured patients, and Xofluza at 50 USD from 168 USD; the platform now lists over 61 drugs, up from 40 in February.[3] Boston faces a 20% health insurance hike, or 97 million USD more, driven by GLP-1 weight loss drugs, prompting limits.[9]

Disruptions include West Suburban Medical Center's closure blamed on billing issues,[11] over 800 facilities at risk from Medicaid cuts, and one million Americans dropping coverage since January.[5] Supply chain talks push reusable textiles to cut waste.[7]

Leaders respond aggressively: pharma firms cut prices via TrumpRx to reach uninsured buyers, contrasting earlier most-favored-nation stalls. M&A surges versus last week's quieter pace, with CMS's 18.6 billion USD Medicare Advantage boost looming today.[12] Consumer behavior shifts to discounted direct buys, easing out-of-pocket burdens but highlighting insurance gaps versus prior stability. Overall, dealmaking accelerates amid policy-driven volatility. (298 words)

For great deals today, check out https://amzn.to/44ci4hQ

This content was created in partnership and with the help of Artificial Intelligence AI